Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis
Review of 31 studies (n=119,053) found no difference in 5-year cumulative incidence of hepatocellular carcinoma for entecavir vs tenofovir disoproxil fumarate. Authors suggest treatment should be guided by patient tolerability and affordability rather than efficacy.
Source:
Lancet Gastroenterology and Hepatology
SPS commentary:
A related commentary suggests that this new study may have solved the controversy from previous research which suggested a difference in risk between these two agents.